---

 Background & Objectives: The prevalence of diabetes and its different methods of treatment have significantly been increased in the last two decades. The actual effect of these treatments is a common topic in the patients’ health and quality of life among these patients has a considerable importance in the community medicine. This study was designed to indicate the quality of life in the diabetic type II patients.

  Methods: This was a cross-sectional, descriptive analytic study in 2004 on 110 type 2 diabetic patients who had referred to Bu Ali Hospital in Ardabil. The patients were randomly selected and took the SF-36 Questionnaire and in the end the data were analyzed by SPSS.

  Results: The average age of the patients was 52.5 with the standard deviation of 11.3 years. 73 of the patients were female (66.4%) and rest of them were male. The average period of sickness among diabetics was 8 years from the time of diagnosis with a standard deviation of 6.2 years. The average of duration of therapy was 7.7 years with 6.1 years standard deviation. 51 patients (46.36%) had the history of hospitalization. Vitality indicator was low in 39.1% of patients. Social functioning was low in 50% of patients. In general, by adding up the quality of life’s various indexes scores based on SF-36 questionnaires standard coefficients, 77% of patients had intermediate and low quality of life.

  Conclusion: According to this study most of the patients in this study had a low quality of life.

---

Background & objectives: Nuclear Factor kappa B (NF-κB), a master switch transcription factor, plays a critical role in the progression and development of hyperglycemia-induced microangiopathy. Hyperglycemia activates NF-κB, and subsequently increases pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1β leading to development of inflammation. Some new studies have revealed the involvement of microRNA-146a (miR-146a) in the pathogenesis of diabetic complications through an NF-κB-dependent negative feedback loop manner. Despite numerous reports indicating changes of plasma miR-146a during hyperglycemia, the origin of this change remains unclear. This study was designed to evaluate the role of NF-κB on the miR-146a gene expression level in human umbilical vein endothelial cells (HUVECs) during a hyperglycemic condition.
Methods: HUVECs were cultured in normal glucose (5 mmol/L), and hyperglycemic (25 mmol/L) endothelial cell growth medium in the six well plates for 24 h. JSH-23 (30 μmol/L), as an inhibitor of NF-κB translocation to the nucleus, was added to the culture medium, 30 min before induction of hyperglycemia. Quantitative Real Time PCR was performed to measure the expression levels of miR-146a and mRNA NF-κB. NF-κB activity was measured by Elisa.
Results: Hyperglycemia markedly increased the NF-κB activity and mRNA level in HUVECs. The expression of miR-146a significantly increased in hyperglycemic group compared to the normoglycemic group. On the other hand, JSH-23 prevented from miR-146a increment in hyperglycemic group and also it increased the mRNA expression level of NF-κB in this group.
Conclusion: This result shows that NF-κB increases the gene expression of miRNA-146a in the early phase of hyperglycemia in HUVECs.